How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

53 results for

Monoclonal Antibody-Mediated Chemotherapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Monoclonal Antibody-Mediated Chemotherapy

Monoclonal Antibody-Mediated Chemotherapy Monoclonal Antibody-Mediated Chemotherapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Monoclonal Antibody-Mediated Chemotherapy Monoclonal Antibody-Mediated Chemotherapy Aka: Monoclonal Antibody-Mediated Chemotherapy , Monoclonal Antibody Immunoconjugate Therapy , Immune Checkpoint Inhibitor From Related Chapters II. History Initially targeted to CD20 on immune cells to treat and Lead to immunosuppressive use in s such as III. Mechanism Targeted to solid tumors (e.g. , and ) Bind extracellular s and receptor binding sites IV. Pharmacokinetics Large molecules (150,000 Da) Water-soluble

2018 FP Notebook

2. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Full Text available with Trip Pro

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses (...) cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management A Scientific Statement From the American Heart Association , MD, MS , MD , MD , MD, FAHA , MD, FAHA , MD , MD, FAHA , MD, FAHA , MD , MD , MD , MD , MD , MD , and RN, FAHA PhDon behalf of the American Heart Association Heart Failure and Transplantation Committee

2015 American Heart Association

3. Monoclonal Antibody-Mediated Chemotherapy

Monoclonal Antibody-Mediated Chemotherapy Monoclonal Antibody-Mediated Chemotherapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Monoclonal Antibody-Mediated Chemotherapy Monoclonal Antibody-Mediated Chemotherapy Aka: Monoclonal Antibody-Mediated Chemotherapy , Monoclonal Antibody Immunoconjugate Therapy , Immune Checkpoint Inhibitor From Related Chapters II. History Initially targeted to CD20 on immune cells to treat and Lead to immunosuppressive use in s such as III. Mechanism Targeted to solid tumors (e.g. , and ) Bind extracellular s and receptor binding sites IV. Pharmacokinetics Large molecules (150,000 Da) Water-soluble

2015 FP Notebook

4. Polyvalent immunoglobulins – Part 1: A rapid review

Events AMR Antibody Mediated Rejection ANSM L’Agence nationale de sécurité du médicament et des produits de santé (in France) BPIDG Belgian Primary Immunodeficiency Group CAAs Coronary Artery Abnormalities CCA Cost Consequences Analysis CEA: Cost effectiveness analysis CIDP Chronic Inflammatory Demyelinating Polyneuropathy CLL Chronic Lymphocytic leukaemia CMA Cost Minimisation Analysis CMV Cytomegalovirus CUA Cost Utility Analysis DAS Disease Activity Score DDD Defined Daily Dose EUnetHTA European (...) b) iatrogenic B cell deficiencies due to chemotherapy, or monoclonal antibodies c) allogenic or autologous hematopoietic stem cell transplantation + recurrent clinically significant infections for which antibiotics were indicated 1. Specialist documents diagnosis 2. Specialist completes reimbursement request form 2 12 months Idiopathic thrombocytopenic purpura + serious bleeding or risk of bleeding 1. Specialist documents diagnosis 2. Specialist completes reimbursement request form 2 12 months

2020 Belgian Health Care Knowledge Centre

5. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care Full Text available with Trip Pro

for AL cardiac amyloidosis was associated with a dismal 1-year survival of 50% because of recurrence of amyloid in the allograft or progression of extracardiac amyloid disease. Recent advances in bortezomib-based chemotherapy strategies for AL amyloidosis and improved patient selection for HTx have led to better outcomes. Single-centre series using a staged approach of HTx followed by autologous bone marrow stem cell transplantation 6-12 months later have increased 1- and 5-year survival rates to 82 (...) %-100% and 65%, respectively. Gray Gilstrap L. Niehaus E. Malhotra R. et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014; 33 : 149-156 , Lee J.Y. Lim S.H. Kim S.J. et al. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid. 2014; 21 : 261-266 , Scott E.C. Heitner S.B. Dibb W. et al. Induction bortezomib in Al amyloidosis followed by high dose

2020 Canadian Cardiovascular Society

7. Management of Anaemia and Iron Deficiency in Patients With Cancer: ESMO Clinical Practice Guidelines

by the EMA has been linked to an increased incidence of antibody-mediated pure red cell aplasia (PRCA). Among 30 patients with renal insuf?ciency who experienced a sudden loss of response after the switch from an epoetin originator, 23 were positive for antibodies to rHuEPO and all of them had PRCA, compared with none in the seven antibody-negative patients [144]. Whether this increased rate of antibody-mediated PRCA cases is actually related to quality-controlled non-originator products or an increased (...) University Hospital Roskilde, Roskilde; 19 University of Copenhagen, Copenhagen, Denmark *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: October 2017. Anaemia and iron de?ciency (ID) are frequent complications in patients with solid tumours or haematological malignancies, par- ticularly in patients treated with chemotherapeutic agents [1–3]. Frequently

2018 European Society for Medical Oncology

8. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines

and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: May 2017. Generalaspectsofimmunecheckpoints blockade Incidenceandepidemiology Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its (...) renal cell carcinoma [10]. For pembrolizumab, the Keynote-002 study, comparing pem- brolizumab at doses of 2 and 10 mg/kg to chemotherapy in ipili- mumab pre-treated metastatic melanoma, showed grade 1 to 2 irAEs in 57%–60% and grade 3 to 4 toxicity in 14% of patients [11]. In the Keynote-006 study comparing pembrolizumab, given at 10 mg/kg either every 3 or 2 weeks, to ipilimumab, treatment- related toxicity was observed in 73%–80% of patients, with 10%– 13.5% having grade 3 or higher AEs [12

2017 European Society for Medical Oncology

9. Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines

). Adults: systolic blood pressure of 30% decrease from that person’s baseline. Table 1. Gell and Coombs classi?cation of hypersensitivity reactions Type I IgE antibody-mediated reactions, e.g. anaphylaxis Type II Antibody-mediated cytotoxic reactions, e.g. haemolytic an- aemia, thrombocytopaenia, blood transfusion reactions Type III Immune complex-mediated hypersensitivity, e.g. serum sick- ness, vasculitis Type IV Delayed T cell-mediated responses, e.g. allergic contact dermatitis, psoriasis (...) : ‘allergic reaction chemotherapy’, ‘allergic reaction mono- clonal antibody’, ‘infusion related reaction chemotherapy’, ‘infu- sion related reaction monoclonal antibody’, ‘allergy reaction cancer’, and ‘infusion related reaction’, 2785 publications were found related to these terms. Figure 2 shows a PRISMA statement Flow Diagram to explain the articles selection. A total of 2503 art- icles were eliminated for the following reasons: no anticancer drugs, articles not speci?cally about IRs, articles

2017 European Society for Medical Oncology

10. Liver transplantation

(Grade III) Immunological evaluation The role of the donor-speci?c human leukocyte antigen alloanti- bodies (DSA) on acute and chronic antibodies-mediated rejection andalsoondifferenthistologicaldamagesuchas?brosis,disease recurrence, biliary complications etc. has been recently raised. The correlation between the cut-off of DSA and liver damage, and moreover, the LT outcome, is still not clear [120]. DSA is an important tool but more research needs to be done in order to understand their usefulness (...) . Recommendation: • The presence of donor-specific alloantibodies has been associated with acute and chronic antibodies-mediated rejection and with several histological damages. The best test and use of anti-DSA is still under study (Grade III) Infection screening Patients with cirrhosis are prone to develop infections that could result in the development of multiple organ failure and death [121].Ascreeningoflatentinfectionsisrequiredinordertotreat apotentiallylethalinfectionbeforeLTandtopreventanexacerba

2015 European Association for the Study of the Liver

11. Gazyvaro - obinutuzumab

and (3) complement-dependent cytotoxicity (CDC) to different degrees. Therapeutic CD20 antibodies can be divided in two subclasses (Type I and Type II) based on the different mechanisms of depleting B-cells. Both subtypes recruit immune effector cells and mediate ADCC. Type I antibodies mediate potent CDC. In contrast, Type II antibodies such as obinutuzumab induce enhanced direct cell death while CDC activity is strongly reduced. CHMP assessment report EMA/CHMP/231450/2014 Page 12/123 (...) HR hazard ratio HRQoL health-related quality of life iDCC independent Data Coordinating Center IgG immunoglobulin G IgHV immunoglobulin heavy chain variable region iNHL indolent non-Hodgkin’s lymphoma IRC Independent Review Committee IRR infusion related reaction ITT intent-to-treat IWCLL International Workshop on Chronic Lymphocytic Leukemia MAA Marketing Authorization Application mAb monoclonal antibody MedDRA Medical Dictionary for Regulatory Activities MRD minimal residual disease NCI

2014 European Medicines Agency - EPARs

12. Lemtrada - alemtuzumab

to high-dose, high-frequency IFNB-1a, nor was it formally studied in patients experiencing disease activity on another MS treatment. The active substance, alemtuzumab, is a humanized monoclonal antibody directed against CD52, one of several specific surface antigens acquired by cells of the hematopoietic system during leukocyte differentiation. Alemtuzumab binds to CD52 which is present at high levels on the surface of T and B lymphocytes and at lower levels on natural killer cells, monocytes (...) to lymphocytes. Assessment report EMA/563018/2013 Page 10/116 2.2. Quality aspects 2.2.1. Introduction The active substance of the finished product is alemtuzumab, a genetically engineered human immunoglobulin subclass gamma 1 (IgG1) kappa monoclonal antibody containing 6 complementarity-determining regions derived from an IgG2a rat monoclonal antibody, specific for the cell surface glycoprotein, CD52. Alemtuzumab binds to CD52, an antigen present at high levels on the surface of B and T lymphocytes

2013 European Medicines Agency - EPARs

13. KHA-CARI adaptation of the KDIGO Guideline for the Care of Kidney Transplant Recipients

and New Zealand are performed outside the two countries. In both countries the ethnicity of donors and recipients is dominantly Caucasian. Asians and Indigenous groups are numerically significant minorities whilst Hispanic and African ethnicities are rare ( 15%, 4 or more HLA mismatches, black race), but not patients at low risk of rejection [30]. Rituximab Rituximab is a monoclonal antibody with activity against CD20 that depletes B cells. Rituximab induction was compared to placebo in a prospective

2012 KHA-CARI Guidelines

14. Ovarian carcinoma glyco-antigen targeted by human IgM antibody. Full Text available with Trip Pro

and demonstrate antibody-mediated binding and cytotoxicity in EOC. Drug and antibody combination effects were determined by calculating the combination index values using the Chou and Talalay method. MAb216 displays direct antibody mediated cytotoxicity on a population of human EOC tumor and ascites samples and EOC cell lines, which express high amounts of poly N-acetyllactosamine epitope, carried by CD147/CD98. Eighty four percent of patient samples, including platin resistant, had a tumor population (...) Ovarian carcinoma glyco-antigen targeted by human IgM antibody. Epithelial Ovarian Cancer (EOC) cells expression of a novel carbohydrate antigen was defined using a human VH4-34 encoded IgM monoclonal antibody (mAb216). MAb216 binds to a poly N-acetyllactosamine epitope expressed on B cells and kills normal and malignant B cells in vitro and in vivo. EOC patient ascites and EOC cell lines were used to study the anti tumor effect of mAb216. Various assays were used to characterize the epitope

2017 PLoS ONE

15. Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

of antibody-mediated cytotoxicity against infected cells by binding to virus emerging from or viral proteins expressed on activated latent cells. Why combined bNAbs? In vivo, multiple bNAbs targeting different epitopes provide better neutralization and antigen recognition than single bNAbs, which suggests that adoptive transfer of multiple bNAbs may lead to superior viral control. Although bNAbs may have neutralization effects that are of greater clinical impact than ADCC, it is possible that antigen (...) between antibody-mediated cell cytotoxicity (ADCC) and NK cell activation as measured by flowcytometry at start of step 4 therapy interruption and level of HIV plasma viral load 8 week later [Innate Activation outcome] [ Time Frame: 8 weeks after end of 30 week of immunotherapy (Analytical Treatment Interruption) ] Level of antibody-mediated cell cytotoxicity (ADCC) by direct measurement of NK cell CD107 degranulation against gp-120 coated targets in the presence of autologous plasma, and NK cell

2018 Clinical Trials

16. Waldenstrom's Macroglobulinaemia

working with a neurologist is encouraged. Anti‐MAG serology and nerve conduction studies are recommended in patients with symptomatic peripheral neuropathy (Grade A1). Chemotherapeutic intervention should be considered in those patients with disabling or rapidly progressive anti‐MAG neuropathy (Grade B1). If chemotherapy is considered appropriate, a rituximab‐containing regimen is appropriate with the final choice of regimen being determined by factors such as performance status, co‐morbidities (...) ‐chemotherapy regimens as detailed above. Recommendations Cryoglobulinaemia should be considered in patients with IgM monoclonal gammopathy

2014 British Committee for Standards in Haematology

17. Photopheresis, extracorporeal

suggested (55), although further studies that focus on this patient population are needed. There is, however, inter-patient variability in the response to ECP in CTCL, so attempts have been made to characterize those patients who are most likely to be responders. The prognostic factors that have been identified include the following (50, 70, 71): ? short duration of disease, preferably 15%) ? absence of prior intensive chemotherapy ? plaque stage disease not covering more than 10–15% of total skin

2013 European Dermatology Forum

18. Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells Full Text available with Trip Pro

by antibody-mediated opsonization, followed by preferential, sustained depletion of proliferating B cells by the auristatin conjugate due to its anti-mitotic action. Delivering potent anti-mitotic agents to B cells via the specificity of monoclonal antibodies provides a means to eliminate pathogenic B cells in NHL with improved risk-benefit profiles over traditional chemotherapeutics.© 2016 Genentech. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological

2017 British journal of pharmacology

19. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance Full Text available with Trip Pro

of resorting to immune-based treatment strategies including either therapeutic vaccination-based active immunotherapy or anti-tumor monoclonal antibody-mediated passive immunotherapy. Particularly attractive, as for research studies and clinical applications, results to be the cytotoxic T-lymphocyte check point blockade by the use of anti-CTLA-4 and PD-1 monoclonal antibodies, particularly when combined with androgen deprivation therapy or radiation. Unlike afore said immune check point inhibitors, both (...) Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance Conventional therapeutic approaches for advanced prostate cancer - such as androgen deprivation, chemotherapy, radiation - come up often against lack of effectiveness because of possible arising of correlative cancer cell resistance and/or inadequate anti-tumor immune conditions. Whence the timeliness

2017 Il Giornale di chirurgia

20. Australian Association for Exercise and Sports Science position statement on exercise and asthma Full Text available with Trip Pro

to be due in part to commensal bowel flora and antibody-mediated immunity. Impairment of the normal resistance mechanisms, including disruption of host flora by most antibiotics, gastric acid suppression, immunosuppression or cytotoxic drugs may result in C. difficile colonising the gastrointestinal tract. For reasons that are not well understood, a proportion of colonised individuals progress to C. difficile infection (CDI) following overgrowth of toxin-producing strains of C. difficile. C. difficile (...) , and hypoalbuminaemia in 76%. CDI usually occurs 5 to 10 days after commencing antibiotic therapy, although symptoms have been described as early as 2 days and as late as 10 weeks after antibiotic treatment. Other reported risk factors include the use of cytotoxic chemotherapy, renal impairment, prior gastrointestinal surgery, severe underlying comorbid conditions, gastric acid-suppressive therapy and prolonged hospital stay. , Although many antibiotics have been implicated, broad spectrum agents such as ampicillin

2011 Clinical Practice Guidelines Portal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>